Our Science

Publications and Presentations

search
Date
Title
October 2020
Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI) BD Alexander, OA Cornely, PG Pappas, R Miller, M Johnson, J Vazquez, L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli, TF Patterson, M Hoenigl, N Azie, DA Angulo
ID Week
October 2020
Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including Isolates with Elevated MIC’s to Echinocandins N. Azie, K. Borroto-Esoda, D. Angulo
ID Week
June 2020
Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi M. Ghannoum, L. Long, R. Sherif, F. Z. Abidi, K. Borroto-Esoda, S. Barat, D. Angulo, N. Wiederhold
ASM Microbe Online
June 2020
Delayed Initiation of the Novel Oral Glucan Synthase Inhibitor, Ibrexafungerp, is Effective in a Murine Model of Invasive Candidiasis caused by Candida auris N.P. Wiederhold, L.K. Najvar, R. Jaramillo, M. Olivo, H. Patterson, S. Barat, K. Borroto-Esoda, G. Catano, T.F. Patterson
UT Health San Antonio, South Texas Veterans Health Care System, SCYNEXIS, Inc.
ASM Microbe Online
April 2020
Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model Stephen Barat, Katyna Borroto-Esoda, Alan Ashbaugh, Melanie Cushion
ECCMID 2020
April 2020
CANDIMAD study: a prospective multi-centre laboratory based survey of antifungal resistance in Candida spp. causing invasive candidiasis in Madrid Judith Diaz-Garcia, Aina Mesquida, María Ángeles Meléndez Carmona, Fernando González-Romo, Cuetara Maria Soledad, Nelly Daniela Zurita Cruz, Maria Muñoz Algarra, Maria Del Coral Garcia, Aída Sánchez, Inmaculada Quiles, Maria Teresa Duran-Valle, Carlos Sanchez-Carrillo, Patricia Muñoz, Pilar Escribano, Jesus Guinea Ortega
February 2020
In vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients Vidya Jagadeesan, Eileen Driscoll, Binghua Hao, Stephen Barat, Katyna Borroto-Esoda, Tom Chen, David Angulo, Cornelius J Clancy, M. Hong Nguyen
AAAM 2020
October 2019
Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study George R. Thompson III, David Angulo
TIMM 2019
October 2019
Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary and Maiken Cavling Arendrup
TIMM 2019
October 2019
Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia S. Barat, D. Angulo
TIMM 2019
< PrevNext >